v3.25.1
Consolidated statement of changes in equity - EUR (€)
€ in Millions
Total
Equity attributable to the owners
Share capital
 [1]
Additional paid-in capital
 [2]
Treasury shares
Accumulated losses
Currency reserve
 [3]
Pensions reserve
Revaluation surplus
 [4]
Other
Non-Controlling Interests
Beginning balance at Mar. 31, 2022 € 57,638 € 55,348 € 4,797 € 149,018 € (7,278) € (122,022) € 28,958 € (751) € 1,227 € 1,399 [5] € 2,290
Issue or reissue of shares 10 10 0 1 122 (113) 0 0 0 0 [5] 0
Share-based payments 135 126 0 126 0 0 0 0 0 0 [5] 9
Transactions with NCI in subsidiaries (1,405) (287) 0 0 0 (287) 0 0 0 0 [5] (1,118)
Dividends (2,900) (2,502) 0 0 0 (2,502) 0 0 0 0 [5] (398)
Comprehensive income/(expense) 11,568 11,267 0 0 0 11,838 (1,374) (160) 0 963 [5] 301
(Loss)/Profit 12,335 11,838 0 0 0 11,838 0 0 0 0 [5] 497
OCI - before tax (598) (368) 0 0 0 0 (1,469) (213) 0 1,314 [5] (230)
OCI - taxes (304) (301) 0 0 0 0 (3) 53 0 (351) [5] (3)
Transfer to the Income statement (334) (334) 0 0 0 0 (334) 0 0 0 [5] 0
Translation of hyperinflationary results 469 432 0 0 0 0 432 0 0 0 [5] 37
Purchase of Treasury shares (563) [6] (563) [6] 0 [6] 0 [6] (563) 0 0 [6] 0 0 [6] 0 [5],[6] 0 [6]
Ending balance at Mar. 31, 2023 64,483 63,399 4,797 149,145 (7,719) (113,086) 27,584 (911) 1,227 2,362 [5] 1,084
Issue or reissue of shares 2 2 0 0 74 (72) 0 0 0 0 [5] 0
Share-based payments 115 108 0 108 0 0 0 0 0 0 [5] 7
Transactions with NCI in subsidiaries (31) (26) 0 0 0 (26) 0 0 0 0 [5] (5)
Share of equity accounted entities change in equity (164) (164) 0 0 0 (164) 0 0 0 0 [5] 0
Dividends (2,689) (2,433) 0 0 0 (2,433) 0 0 0 0 [5] (256)
Comprehensive income/(expense) (718) (920) 0 0 0 1,140 (254) (58) 0 (1,748) [5] 202
(Loss)/Profit 1,505 1,140 0 0 0 1,140 0 0 0 0 [5] 365
OCI - before tax (3,426) (3,234) 0 0 0 0 (826) (77) 0 (2,331) [5] (192)
OCI - taxes 602 602 0 0 0 0 0 19 0 583 [5] 0
Transfer to the Income statement 23 23 0 0 0 0 23 0 0 0 [5] 0
Translation of hyperinflationary results 578 549 0 0 0 0 549 0 0 0 [5] 29
Ending balance at Mar. 31, 2024 60,998 59,966 4,797 149,253 (7,645) (114,641) 27,330 (969) 1,227 614 [5],[7] 1,032
Issue or reissue of shares 3 3 0 0 84 (81) 0 0 0 0 [7] 0
Share-based payments 110 103 0 103 0 0 0 0 0 0 [7] 7
Transactions with NCI in subsidiaries 3 (47) 0 0 0 (47) 0 0 0 0 [7] 50
Dividends (2,041) (1,795) 0 0 0 (1,795) 0 0 0 0 [7] (246)
Comprehensive income/(expense) (3,157) (3,485) 0 0 0 (4,169) 531 1 0 152 [7] 328
(Loss)/Profit (3,746) (4,169) 0 0 0 (4,169) 0 0 0 0 [7] 423
OCI - before tax (25) 30 0 0 0 0 (162) (12) 0 204 [7] (55)
OCI - taxes (65) (65) 0 0 0 0 0 13 0 (78) [7] 0
Transfer to the Income statement 141 141 0 0 0 0 115 0 0 26 [7] 0
Translation of hyperinflationary results 538 578 0 0 0 0 578 0 0 0 [7] (40)
Purchase of Treasury shares [7] (2,000) (2,000) 0 0 (2,000) 0 0 0 0 0 [5] 0
Cancellation of shares 0 0 (478) 478 2,770 (2,770) 0 0 0 0 [7] 0
Ending balance at Mar. 31, 2025 € 53,916 € 52,745 € 4,319 € 149,834 € (6,791) € (123,503) € 27,861 € (968) € 1,227 € 766 [7] € 1,171
[1] See note 17 ‘Called up share capital’.
[2] Includes share premium, capital reserve, capital redemption reserve, merger reserve and share-based payment reserve. The merger reserve was derived from acquisitions made prior to 31 March 2004 and subsequently allocated to additional paid-in capital on adoption of IFRS.
[3] The currency reserve is used to record cumulative translation differences on the assets and liabilities of foreign operations. These differences are recycled to the income statement on disposal of the foreign operation.
[4] The revaluation surplus derives from acquisitions of subsidiaries made before the Group’s adoption of IFRS 3 (Revised) on 1 April 2010 and comprises the amounts arising from recognising the Group’s pre-existing equity interest in the acquired subsidiary at fair value.
[5] Principally includes the impact of the Group’s cash flow hedges with €47 million net gain deferred to other comprehensive income during the year (2024: €2,037 million net loss; 2023: €2,322 million net gain) and €27 million net loss (2024: €254 million net gain; 2023: €896 million net gain) recycled to the consolidated income statement. These hedges primarily relate to foreign exchange exposure on fixed borrowings, with any foreign exchange on nominal balances directly impacting the income statements in each period but interest cash flows unwinding to the consolidated income statement over the life of the hedges, up to 2064. See note 22 ‘Capital and financial risk management’.
[6] Represents the irrevocable and non-discretionary share buyback programmes which completed on 15 March 2023.
[7] Represents the irrevocable and non-discretionary share buyback programmes which completed on 6 August 2024, 13 November 2024, 22 January 2025 and the programme that commenced on 4 February 2025.